• 1. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651
• 2. Evolution of shape, size, and areal density of a single plane of Si nanocrystals embedded in SiO2 matrix studied by atom probe tomography
  Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622
• 3. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 4. Emerging investigators
  Polym. Chem., 2015,6, 5501-5502
• 5. Excitation energies from ground-state density-functionals by means of generator coordinates
  A. B. F. da Silva,K. Capelle Phys. Chem. Chem. Phys., 2009,11, 4564-4569

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolidines Pyrrolidinecarboxamides
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolidines Pyrrolidine carboxylic acids and derivatives Pyrrolidinecarboxamides

Introduction to Compound with CAS No. 2034446-38-1 and Product Name: 1-{3-[(6-methoxypyridazin-3-yl)oxy]pyrrolidine-1-carbonyl}imidazolidin-2-one

The compound with the CAS number 2034446-38-1 and the product name 1-{3-[(6-methoxypyridazin-3-yl)oxy]pyrrolidine-1-carbonyl}imidazolidin-2-one represents a significant advancement in the field of pharmaceutical chemistry. This compound has garnered attention due to its unique structural features and potential applications in drug development. The molecular structure incorporates several key functional groups that contribute to its biological activity, making it a promising candidate for further research and therapeutic applications.

At the core of this compound's identity is its intricate molecular framework, which includes a pyrrolidine ring linked to an imidazolidinone moiety. The presence of a 6-methoxypyridazin-3-yl group attached through an oxygen atom to the pyrrolidine ring introduces a layer of complexity that is often associated with enhanced biological interactions. This structural motif is particularly noteworthy because it has been observed to influence the pharmacokinetic and pharmacodynamic properties of molecules in various drug classes.

Recent studies have highlighted the importance of pyrrolidine derivatives in medicinal chemistry, particularly for their role as bioisosteres that can modulate receptor binding and metabolic stability. The incorporation of a pyrrolidine scaffold into the imidazolidinone core in this compound suggests potential interactions with biological targets that may be relevant for therapeutic intervention. Additionally, the 6-methoxypyridazine moiety is known for its ability to enhance binding affinity and selectivity, which could be leveraged in the design of next-generation pharmaceuticals.

The imidazolidinone component of the molecule is another critical feature that contributes to its overall activity. This heterocyclic ring system is commonly found in bioactive compounds and has been shown to exhibit a range of biological effects, including anti-inflammatory, antimicrobial, and anticancer properties. The specific arrangement of atoms within the imidazolidinone ring in this compound may contribute to its unique pharmacological profile, making it a valuable scaffold for further derivatization and optimization.

In the context of current research trends, this compound aligns well with the growing interest in multitargeted drug discovery. The presence of multiple functional groups that can interact with different biological pathways suggests that it may have applications beyond a single therapeutic indication. This multitargeting approach is increasingly recognized as a key strategy for developing drugs with broader efficacy and reduced side effects. The potential of this compound to interact with multiple targets makes it an attractive candidate for further exploration in drug development pipelines.

Furthermore, the structural features of this compound make it amenable to modifications that could enhance its pharmacological properties. For instance, the oxygen atom linking the pyrrolidine ring to the 6-methoxypyridazine group could be modified to introduce additional functional diversity. Such modifications could lead to derivatives with improved solubility, bioavailability, or target specificity. The flexibility offered by this molecular framework allows for extensive chemical manipulation, which is essential for optimizing drug candidates for clinical use.

The synthesis of this compound also reflects advancements in synthetic methodologies that enable the construction of complex molecular architectures efficiently. Modern synthetic techniques have made it possible to access highly functionalized heterocycles like those present in this molecule with greater ease than was previously possible. This accessibility is crucial for drug discovery programs, as it allows researchers to rapidly explore new chemical space and identify novel lead compounds.

Evaluation of this compound's potential involves considering its interaction with biological targets at both the molecular and cellular levels. Computational modeling and experimental techniques such as X-ray crystallography can provide insights into how this molecule binds to its intended targets and how these interactions influence its biological activity. Such studies are essential for understanding the mechanisms by which drugs exert their effects and for identifying opportunities for optimization.

The pharmaceutical industry has increasingly recognized the value of small molecules like this one as tools for therapeutic intervention. Their ability to modulate biological processes at specific sites within cells makes them powerful candidates for treating a wide range of diseases. As research continues to uncover new biological pathways and targets, compounds like this one will play an important role in addressing unmet medical needs.

In conclusion, the compound with CAS number 2034446-38-1 and product name 1-{3-[(6-methoxypyridazin-3-yl)oxy]pyrrolidine-1-carbonyl}imidazolidin-2-one represents a significant advancement in pharmaceutical chemistry. Its unique structural features and potential applications make it a promising candidate for further research and development. As interest in multitargeted drug discovery grows, compounds like this one will continue to be explored as valuable tools for therapeutic intervention.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)